Tag: Multitude Therapeutics

Multitude Therapeutics Announces Encouraging Interim Phase I/II Results from Ongoing First-in-Human Study Evaluating its MUC18-directed Antibody-Drug-Conjugate, AMT-253, in Melanoma and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting
Food Security

Multitude Therapeutics Announces Encouraging Interim Phase I/II Results from Ongoing First-in-Human Study Evaluating its MUC18-directed Antibody-Drug-Conjugate, AMT-253, in Melanoma and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting

AMT-253 is a potential first-in-class MUC18-directed ADC with a proprietary linker-payload design   AMT-253 demonstrated a manageable safety profile, consistent with other TOP1-inhibitor based ADCs Promising antitumor activity was observed in heavily pretreated patients with […]

Multitude Therapeutics Announces Encouraging Interim Phase I/II Results from Ongoing First-in-Human Study Evaluating its MUC18-directed Antibody-Drug-Conjugate, AMT-253, in Melanoma and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting
Environmental Health

Multitude Therapeutics Announces Encouraging Interim Phase I/II Results from Ongoing First-in-Human Study Evaluating its MUC18-directed Antibody-Drug-Conjugate, AMT-253, in Melanoma and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting

AMT-253 is a potential first-in-class MUC18-directed ADC with a proprietary linker-payload design   AMT-253 demonstrated a manageable safety profile, consistent with other TOP1-inhibitor based ADCs Promising antitumor activity was observed in heavily pretreated patients with […]